Z‐Ligustilide inhibits benzo(a)pyrene‐induced CYP1A1 upregulation in cultured human keratinocytes via ROS‐dependent Nrf2 activation

  • Zhouwei Wu
    Department of Dermatology Graduate School of Medical Sciences Kyushu University Fukuoka Japan
  • Hiroshi Uchi
    Department of Dermatology Graduate School of Medical Sciences Kyushu University Fukuoka Japan
  • Saori Morino‐Koga
    Department of Dermatology Graduate School of Medical Sciences Kyushu University Fukuoka Japan
  • Akiko Nakamura‐Satomura
    Department of Dermatology Graduate School of Medical Sciences Kyushu University Fukuoka Japan
  • Kazuyo Kita
    Department of Dermatology Graduate School of Medical Sciences Kyushu University Fukuoka Japan
  • Weimin Shi
    Department of Dermatology Shanghai First People's Hospital Shanghai Jiaotong University Shanghai China
  • Masutaka Furue
    Department of Dermatology Graduate School of Medical Sciences Kyushu University Fukuoka Japan

この論文をさがす

説明

<jats:title>Abstract</jats:title><jats:p>Benzo(a)pyrene (BaP), a polycyclic aromatic hydrocarbon (PAH), is an environmental contaminant that can induce cytochrome P4501A1 (CYP1A1) upregulation via aryl hydrocarbon receptor (AhR) activation and provoke inflammation. Here, we investigated the effect of Z‐Ligustilide, an active ingredient isolated from the medicinal plants <jats:italic>Cnidium officinale</jats:italic> and <jats:italic>Angelica acutiloba</jats:italic>, on BaP‐induced CYP1A1 upregulation in normal human epidermal keratinocytes (NHEKs) as well as its underlying mechanisms. Z‐Ligustilide significantly inhibited BaP‐induced CYP1A1 upregulation in NHEKs. Treatment of NHEKs with Z‐Ligustilide induced Nuclear factor‐E2‐related factor 2 (Nrf2) nuclear translocation and expression of the Nrf2‐regulated genes for haeme oxygenase‐1 (HO‐1) and NAD(P)H:quinine oxidoreductase‐1 (NQO1). AhR silencing, SB203580 (a p38 inhibitor), SP600125 (a JNK inhibitor), U0126 (a MEK inhibitor) and LY294002 (a PI3K inhibitor) did not suppress Z‐Ligustilide‐induced Nrf2 activation. Moreover, treatment of NHEKs with Z‐Ligustilide increased reactive oxygen species (ROS) and L‐N‐acetylcysteine (L‐NAC, an antioxidant) attenuated Z‐ligustilide‐induced Nrf2 nuclear translocation and HO‐1 expression. L‐NAC or knock‐down of Nrf2 significantly attenuated the inhibitory effects of Z‐Ligustilide on BaP‐induced CYP1A1 upregulation in NHEKs. Taken together, these findings suggest that Z‐Ligustilide can suppress BaP‐induced CYP1A1 upregulation through ROS‐dependent Nrf2 pathway activation and may be beneficial in preventing or treating BaP‐induced skin damage.</jats:p>

収録刊行物

被引用文献 (2)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ